Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Limited, an Australian firm focusing on cancer and fibrosis treatments, has announced an update to Director Dr. Robert Peach’s interests, indicating a significant acquisition of 827,268 shares at $0.055 each. This move, as detailed in the Appendix 3Y Change of Director’s Interest Notice, reflects changes in the director’s stake in the company, which could interest investors tracking insider activities.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
